Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors.
Dal Bello MG, Alama A, Barletta G, Coco S, Truini A, Vanni I, Boccardo S, Genova C, Rijavec E, Biello F, Bottoni G, Sambuceti G, Grossi F. Dal Bello MG, et al. Among authors: boccardo s. Int J Cancer. 2015 Dec 15;137(12):2947-58. doi: 10.1002/ijc.29647. Epub 2015 Jul 15. Int J Cancer. 2015. PMID: 26089022
The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients.
Dal Bello MG, Filiberti RA, Alama A, Orengo AM, Mussap M, Coco S, Vanni I, Boccardo S, Rijavec E, Genova C, Biello F, Barletta G, Rossi G, Tagliamento M, Maggioni C, Grossi F. Dal Bello MG, et al. Among authors: boccardo s. J Transl Med. 2019 Mar 8;17(1):74. doi: 10.1186/s12967-019-1828-0. J Transl Med. 2019. PMID: 30849967 Free PMC article.
Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer.
Salvi S, Fontana V, Boccardo S, Merlo DF, Margallo E, Laurent S, Morabito A, Rijavec E, Dal Bello MG, Mora M, Ratto GB, Grossi F, Truini M, Pistillo MP. Salvi S, et al. Among authors: boccardo s. Cancer Immunol Immunother. 2012 Sep;61(9):1463-72. doi: 10.1007/s00262-012-1211-y. Epub 2012 Feb 9. Cancer Immunol Immunother. 2012. PMID: 22318401 Free PMC article.
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer.
Tagliamento M, Genova C, Rijavec E, Rossi G, Biello F, Dal Bello MG, Alama A, Coco S, Boccardo S, Grossi F. Tagliamento M, et al. Among authors: boccardo s. Expert Opin Pharmacother. 2018 Dec;19(18):2055-2062. doi: 10.1080/14656566.2018.1540591. Epub 2018 Nov 3. Expert Opin Pharmacother. 2018. PMID: 30392436 Review.
Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer.
Ottonello S, Genova C, Cossu I, Fontana V, Rijavec E, Rossi G, Biello F, Dal Bello MG, Tagliamento M, Alama A, Coco S, Boccardo S, Vanni I, Ferlazzo G, Moretta L, Grossi F, Mingari MC, Carrega P, Pietra G. Ottonello S, et al. Among authors: boccardo s. Front Immunol. 2020 Feb 7;11:125. doi: 10.3389/fimmu.2020.00125. eCollection 2020. Front Immunol. 2020. PMID: 32117275 Free PMC article.
57 results